Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome

S. B. Saslow, M. D. O'Brien, Michael Camilleri, M. Von der Ohe, H. A. Homburger, G. G. Klee, Henry Clement Pitot, J. Rubin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: Previous studies showed increased plasma motilin and substance P concentrations and accelerated motor function in the small bowel and colon in patients with carcinoid diarrhea. Octreotide is beneficial in patients with carcinoid syndrome. Our hypothesis was that octreotide inhibits accelerated motility and gut neuropeptides in carcinoid syndrome. Methods: In 12 patients with metastatic carcinoid syndrome, we investigated the effect of octreotide 50 μg s.c. t.i.d (n = 6) or placebo (n = 6) on postprandial symptoms, GI transit, colonic motility, and circulating levels of selected circulating peptides and amines. Results: Octreotide reduced postprandial flushing (p = 0.03) but not pain. Octreotide significantly retarded overall colonic transit and proximal colonic emptying (p < 0.05); it tended to prolong small bowel transit time (p = 0.13) and to reduce postprandial colonic tone (p = 0.08) compared with placebo. Octreotide also reduced circulating levels of peptide YY, neurotensin, vasoactive intestinal polypeptide, and substance P but had no effect on plasma motilin, neuropeptide Y, calcitonin gene-related peptide, or histamine after meal ingestion. Conclusion: Octreotide ameliorates gut motor dysfunctions that characterize carcinoid diarrhea; the potential role of specific antagonism of serotonin, substance P, and vasoactive intestinal polypeptide alone or in combination with agents that inhibit their release in carcinoid diarrhea deserves further study.

Original languageEnglish (US)
Pages (from-to)2250-2256
Number of pages7
JournalAmerican Journal of Gastroenterology
Volume92
Issue number12
StatePublished - 1997

Fingerprint

Octreotide
Carcinoid Tumor
Substance P
Motilin
Diarrhea
Vasoactive Intestinal Peptide
Placebos
Peptide YY
Neurotensin
Calcitonin Gene-Related Peptide
Neuropeptide Y
Inhibition (Psychology)
Neuropeptides
Histamine
Amines
Meals
Serotonin
Colon
Eating
Pain

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Saslow, S. B., O'Brien, M. D., Camilleri, M., Von der Ohe, M., Homburger, H. A., Klee, G. G., ... Rubin, J. (1997). Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. American Journal of Gastroenterology, 92(12), 2250-2256.

Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. / Saslow, S. B.; O'Brien, M. D.; Camilleri, Michael; Von der Ohe, M.; Homburger, H. A.; Klee, G. G.; Pitot, Henry Clement; Rubin, J.

In: American Journal of Gastroenterology, Vol. 92, No. 12, 1997, p. 2250-2256.

Research output: Contribution to journalArticle

Saslow, SB, O'Brien, MD, Camilleri, M, Von der Ohe, M, Homburger, HA, Klee, GG, Pitot, HC & Rubin, J 1997, 'Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome', American Journal of Gastroenterology, vol. 92, no. 12, pp. 2250-2256.
Saslow SB, O'Brien MD, Camilleri M, Von der Ohe M, Homburger HA, Klee GG et al. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. American Journal of Gastroenterology. 1997;92(12):2250-2256.
Saslow, S. B. ; O'Brien, M. D. ; Camilleri, Michael ; Von der Ohe, M. ; Homburger, H. A. ; Klee, G. G. ; Pitot, Henry Clement ; Rubin, J. / Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. In: American Journal of Gastroenterology. 1997 ; Vol. 92, No. 12. pp. 2250-2256.
@article{479dd2a887a64964b5333e06d97a12fb,
title = "Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome",
abstract = "Objectives: Previous studies showed increased plasma motilin and substance P concentrations and accelerated motor function in the small bowel and colon in patients with carcinoid diarrhea. Octreotide is beneficial in patients with carcinoid syndrome. Our hypothesis was that octreotide inhibits accelerated motility and gut neuropeptides in carcinoid syndrome. Methods: In 12 patients with metastatic carcinoid syndrome, we investigated the effect of octreotide 50 μg s.c. t.i.d (n = 6) or placebo (n = 6) on postprandial symptoms, GI transit, colonic motility, and circulating levels of selected circulating peptides and amines. Results: Octreotide reduced postprandial flushing (p = 0.03) but not pain. Octreotide significantly retarded overall colonic transit and proximal colonic emptying (p < 0.05); it tended to prolong small bowel transit time (p = 0.13) and to reduce postprandial colonic tone (p = 0.08) compared with placebo. Octreotide also reduced circulating levels of peptide YY, neurotensin, vasoactive intestinal polypeptide, and substance P but had no effect on plasma motilin, neuropeptide Y, calcitonin gene-related peptide, or histamine after meal ingestion. Conclusion: Octreotide ameliorates gut motor dysfunctions that characterize carcinoid diarrhea; the potential role of specific antagonism of serotonin, substance P, and vasoactive intestinal polypeptide alone or in combination with agents that inhibit their release in carcinoid diarrhea deserves further study.",
author = "Saslow, {S. B.} and O'Brien, {M. D.} and Michael Camilleri and {Von der Ohe}, M. and Homburger, {H. A.} and Klee, {G. G.} and Pitot, {Henry Clement} and J. Rubin",
year = "1997",
language = "English (US)",
volume = "92",
pages = "2250--2256",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome

AU - Saslow, S. B.

AU - O'Brien, M. D.

AU - Camilleri, Michael

AU - Von der Ohe, M.

AU - Homburger, H. A.

AU - Klee, G. G.

AU - Pitot, Henry Clement

AU - Rubin, J.

PY - 1997

Y1 - 1997

N2 - Objectives: Previous studies showed increased plasma motilin and substance P concentrations and accelerated motor function in the small bowel and colon in patients with carcinoid diarrhea. Octreotide is beneficial in patients with carcinoid syndrome. Our hypothesis was that octreotide inhibits accelerated motility and gut neuropeptides in carcinoid syndrome. Methods: In 12 patients with metastatic carcinoid syndrome, we investigated the effect of octreotide 50 μg s.c. t.i.d (n = 6) or placebo (n = 6) on postprandial symptoms, GI transit, colonic motility, and circulating levels of selected circulating peptides and amines. Results: Octreotide reduced postprandial flushing (p = 0.03) but not pain. Octreotide significantly retarded overall colonic transit and proximal colonic emptying (p < 0.05); it tended to prolong small bowel transit time (p = 0.13) and to reduce postprandial colonic tone (p = 0.08) compared with placebo. Octreotide also reduced circulating levels of peptide YY, neurotensin, vasoactive intestinal polypeptide, and substance P but had no effect on plasma motilin, neuropeptide Y, calcitonin gene-related peptide, or histamine after meal ingestion. Conclusion: Octreotide ameliorates gut motor dysfunctions that characterize carcinoid diarrhea; the potential role of specific antagonism of serotonin, substance P, and vasoactive intestinal polypeptide alone or in combination with agents that inhibit their release in carcinoid diarrhea deserves further study.

AB - Objectives: Previous studies showed increased plasma motilin and substance P concentrations and accelerated motor function in the small bowel and colon in patients with carcinoid diarrhea. Octreotide is beneficial in patients with carcinoid syndrome. Our hypothesis was that octreotide inhibits accelerated motility and gut neuropeptides in carcinoid syndrome. Methods: In 12 patients with metastatic carcinoid syndrome, we investigated the effect of octreotide 50 μg s.c. t.i.d (n = 6) or placebo (n = 6) on postprandial symptoms, GI transit, colonic motility, and circulating levels of selected circulating peptides and amines. Results: Octreotide reduced postprandial flushing (p = 0.03) but not pain. Octreotide significantly retarded overall colonic transit and proximal colonic emptying (p < 0.05); it tended to prolong small bowel transit time (p = 0.13) and to reduce postprandial colonic tone (p = 0.08) compared with placebo. Octreotide also reduced circulating levels of peptide YY, neurotensin, vasoactive intestinal polypeptide, and substance P but had no effect on plasma motilin, neuropeptide Y, calcitonin gene-related peptide, or histamine after meal ingestion. Conclusion: Octreotide ameliorates gut motor dysfunctions that characterize carcinoid diarrhea; the potential role of specific antagonism of serotonin, substance P, and vasoactive intestinal polypeptide alone or in combination with agents that inhibit their release in carcinoid diarrhea deserves further study.

UR - http://www.scopus.com/inward/record.url?scp=0030814876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030814876&partnerID=8YFLogxK

M3 - Article

C2 - 9399764

AN - SCOPUS:0030814876

VL - 92

SP - 2250

EP - 2256

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 12

ER -